Legend Biotech Says In Vivo CAR-T Candidate LB2501 Delivers Early Proof-of-Concept in Lymphoma

MT Newswires Live

Jun 15

Legend Biotech's (LEGN) experimental in vivo CD19/CD20 dual-targeting CAR-T candidate, LB2501, showed early clinical proof-of-concept in an ongoing phase 1 trial involving patients with relapsed or refractory B-cell non-Hodgkin lymphoma, the company said Sunday.

At the higher dose, a single infusion of LB2501 produced a 100% objective response rate and an 83.3% complete response rate in six patients, while across both dose levels the objective and complete response rates were 50% and 41.7%, respectively, the company said.

LB2501 showed dose-dependent CAR-T expansion and a favorable safety profile, with no dose-limiting toxicities, serious adverse events, neurotoxicity, or deaths, Legend Biotech added.

Data presented at the European Hematology Association 2026 Congress supported the feasibility of generating CAR-T cells directly in patients and reinforced Legend's efforts to expand its next-generation cell therapy portfolio beyond CARVYKTI.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2643275160"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2643275160\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2643275160?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-15 16:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2643275160","market":"nz","top_or_hot":-1,"title":"Legend Biotech Says In Vivo CAR-T Candidate LB2501 Delivers Early Proof-of-Concept in Lymphoma","media":"MT Newswires Live","content":"<html><body><p> Legend Biotech's (LEGN) experimental in vivo CD19/CD20 dual-targeting CAR-T candidate, LB2501, showed early clinical proof-of-concept in an ongoing phase 1 trial involving patients with relapsed or refractory B-cell non-Hodgkin lymphoma, the company said Sunday.</p><p>At the higher dose, a single infusion of LB2501 produced a 100% objective response rate and an 83.3% complete response rate in six patients, while across both dose levels the objective and complete response rates were 50% and 41.7%, respectively, the company said.</p><p>LB2501 showed dose-dependent CAR-T expansion and a favorable safety profile, with no dose-limiting toxicities, serious adverse events, neurotoxicity, or deaths, Legend Biotech added.</p><p>Data presented at the European Hematology Association 2026 Congress supported the feasibility of generating CAR-T cells directly in patients and reinforced Legend's efforts to expand its next-generation cell therapy portfolio beyond CARVYKTI.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Legend Biotech Says In Vivo CAR-T Candidate LB2501 Delivers Early Proof-of-Concept in Lymphoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLegend Biotech Says In Vivo CAR-T Candidate LB2501 Delivers Early Proof-of-Concept in Lymphoma\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-15 16:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Legend Biotech's (LEGN) experimental in vivo CD19/CD20 dual-targeting CAR-T candidate, LB2501, showed early clinical proof-of-concept in an ongoing phase 1 trial involving patients with relapsed or refractory B-cell non-Hodgkin lymphoma, the company said Sunday.</p><p>At the higher dose, a single infusion of LB2501 produced a 100% objective response rate and an 83.3% complete response rate in six patients, while across both dose levels the objective and complete response rates were 50% and 41.7%, respectively, the company said.</p><p>LB2501 showed dose-dependent CAR-T expansion and a favorable safety profile, with no dose-limiting toxicities, serious adverse events, neurotoxicity, or deaths, Legend Biotech added.</p><p>Data presented at the European Hematology Association 2026 Congress supported the feasibility of generating CAR-T cells directly in patients and reinforced Legend's efforts to expand its next-generation cell therapy portfolio beyond CARVYKTI.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LEGN","symbol_name":"传奇生物","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2643275160","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2643275160","pubTimestamp":1781510821,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Legend Biotech's  experimental in vivo CD19/CD20 dual-targeting CAR-T candidate, LB2501, showed early clinical proof-of-concept in an ongoing phase 1 trial involving patients with relapsed or refractory B-cell non-Hodgkin lymphoma, the company said Sunday.At the higher dose, a single infusion of LB2501 produced a 100% objective response rate and an 83.3% complete response rate in six patients, while across both dose levels the objective and complete response rates were 50% and 41.7%, respectively, the company said.LB2501 showed dose-dependent CAR-T expansion and a favorable safety profile, with no dose-limiting toxicities, serious adverse events, neurotoxicity, or deaths, Legend Biotech added.Data presented at the European Hematology Association 2026 Congress supported the feasibility of generating CAR-T cells directly in patients and reinforced Legend's efforts to expand its next-generation cell therapy portfolio beyond CARVYKTI.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LEGN":"传奇生物","BK4230":"旅客陆运","BK4139":"生物科技","BK4581":"高盛持仓","XBI":"SPDR S&P Biotech ETF","BK4505":"高瓴资本持仓","BK4022":"陆运","CAR":"安飞士","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"传奇生物表示体内CAR-T候选药物LB2501可在淋巴瘤中提供早期概念验证","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CAR":1.5,"LEGN":1.5,"XBI":1.5},"content_text":"Legend Biotech's (LEGN) experimental in vivo CD19/CD20 dual-targeting CAR-T candidate, LB2501, showed early clinical proof-of-concept in an ongoing phase 1 trial involving patients with relapsed or refractory B-cell non-Hodgkin lymphoma, the company said Sunday.At the higher dose, a single infusion of LB2501 produced a 100% objective response rate and an 83.3% complete response rate in six patients, while across both dose levels the objective and complete response rates were 50% and 41.7%, respectively, the company said.LB2501 showed dose-dependent CAR-T expansion and a favorable safety profile, with no dose-limiting toxicities, serious adverse events, neurotoxicity, or deaths, Legend Biotech added.Data presented at the European Hematology Association 2026 Congress supported the feasibility of generating CAR-T cells directly in patients and reinforced Legend's efforts to expand its next-generation cell therapy portfolio beyond CARVYKTI.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}